Login to Your Account



Inventiva, BI ink $189M fibrotic disease pact

By Nuala Moran
Staff Writer

Tuesday, May 31, 2016

LONDON – Inventiva SAS has sealed a €170 million (US$189 million) deal with Boehringer Ingelheim GmbH for the discovery and preclinical development of small molecules aimed at a target that represents a potentially new approach to treating IPF and other fibrotic diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription